Cargando…
Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer
A natural bioactive compound named calotropone has been reported as a drug candidate for several cancers, including pancreatic cancers. Herein, we used molecular docking approach to test the possible mechanisms of action of calotropone in inhibiting the growth of pancreatic cell cancer with gemcitab...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820343/ https://www.ncbi.nlm.nih.gov/pubmed/35223440 http://dx.doi.org/10.4103/japtr.japtr_143_21 |
_version_ | 1784646206891229184 |
---|---|
author | Purnama, Agnia Rizki, Diva Rayyan Qanita, Intan Iqhrammullah, Muhammad Ahmad, Khairunnas Mardina, Vivi Puspita, Kana Hasballah, Kartini |
author_facet | Purnama, Agnia Rizki, Diva Rayyan Qanita, Intan Iqhrammullah, Muhammad Ahmad, Khairunnas Mardina, Vivi Puspita, Kana Hasballah, Kartini |
author_sort | Purnama, Agnia |
collection | PubMed |
description | A natural bioactive compound named calotropone has been reported as a drug candidate for several cancers, including pancreatic cancers. Herein, we used molecular docking approach to test the possible mechanisms of action of calotropone in inhibiting the growth of pancreatic cell cancer with gemcitabine as the positive control. By employing AutoDock Vina, we studied the molecular interaction between calotropone and pancreatic cancer-associated proteins, namely Glucosaminyl (N-Acetyl) Transferase 3, Glutamic-Oxaloacetic Transaminase 1, Tyrosine-protein kinase Met (c-Met), peroxisome proliferator-activated receptor γ, Budding Uninhibited by Benzimidazole 1, A Disintegrin and Metalloproteinase 10, Sex-determining region Y and Nuclear Factor kappa Beta (Nf-Kβ). Higher affinity energies of calotropone toward the aforementioned proteins (ranging from ‒7.3 to ‒9.3 kcal/mol) indicate that calotropone may work in the same manner as anticancer drug gemcitabine. Highest docking score was found at the interaction of calotropone and Nf-Kβ (‒9.3 kcal/mol). |
format | Online Article Text |
id | pubmed-8820343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-88203432022-02-24 Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer Purnama, Agnia Rizki, Diva Rayyan Qanita, Intan Iqhrammullah, Muhammad Ahmad, Khairunnas Mardina, Vivi Puspita, Kana Hasballah, Kartini J Adv Pharm Technol Res Original Article A natural bioactive compound named calotropone has been reported as a drug candidate for several cancers, including pancreatic cancers. Herein, we used molecular docking approach to test the possible mechanisms of action of calotropone in inhibiting the growth of pancreatic cell cancer with gemcitabine as the positive control. By employing AutoDock Vina, we studied the molecular interaction between calotropone and pancreatic cancer-associated proteins, namely Glucosaminyl (N-Acetyl) Transferase 3, Glutamic-Oxaloacetic Transaminase 1, Tyrosine-protein kinase Met (c-Met), peroxisome proliferator-activated receptor γ, Budding Uninhibited by Benzimidazole 1, A Disintegrin and Metalloproteinase 10, Sex-determining region Y and Nuclear Factor kappa Beta (Nf-Kβ). Higher affinity energies of calotropone toward the aforementioned proteins (ranging from ‒7.3 to ‒9.3 kcal/mol) indicate that calotropone may work in the same manner as anticancer drug gemcitabine. Highest docking score was found at the interaction of calotropone and Nf-Kβ (‒9.3 kcal/mol). Wolters Kluwer - Medknow 2022 2022-01-21 /pmc/articles/PMC8820343/ /pubmed/35223440 http://dx.doi.org/10.4103/japtr.japtr_143_21 Text en Copyright: © 2022 Journal of Advanced Pharmaceutical Technology & Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Purnama, Agnia Rizki, Diva Rayyan Qanita, Intan Iqhrammullah, Muhammad Ahmad, Khairunnas Mardina, Vivi Puspita, Kana Hasballah, Kartini Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer |
title | Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer |
title_full | Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer |
title_fullStr | Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer |
title_full_unstemmed | Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer |
title_short | Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer |
title_sort | molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820343/ https://www.ncbi.nlm.nih.gov/pubmed/35223440 http://dx.doi.org/10.4103/japtr.japtr_143_21 |
work_keys_str_mv | AT purnamaagnia moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer AT rizkidivarayyan moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer AT qanitaintan moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer AT iqhrammullahmuhammad moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer AT ahmadkhairunnas moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer AT mardinavivi moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer AT puspitakana moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer AT hasballahkartini moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer |